2023 Novo Holdings Seed Investments Team Annual Review/Business Update
- Several significant portfolio financing rounds
- Launch of SeedLab accelerating company creation with wet lab
- Four portfolio companies reported significant clinical data
Copenhagen, Denmark, 4 January 2024 – Seed Investments, the early-stage investment and company creation team of Novo Holdings, today publishes its review of 2023 – a year of developing and building for long-term results.
The Seed Investments team’s ambition is to incubate, build and invest in breakthrough life science companies. We proactively collaborate with innovators globally and take the lead in building and investing in early-stage start-ups. 2023 saw the team focus on ensuring the portfolio has the right conditions to progress towards value inflection points, while continuing to build next generation companies. For more information, please visit link on our website.
Søren Møller, Managing Partner at Seed Investments, said: “2023 has been a successful year for Seed Investments with more than $460m raised to our portfolio. Despite market headwinds faced by biotech companies, we continued to actively invest in the sector and continue to see an unparalleled level of innovation.
This year, Seed Investments launched SeedLab, our wet laboratory in Denmark, to incubate scientific concepts and novel ideas and thereby reducing risk prior to company creation. As we look forward to 2024, our focus remains on creating and supporting innovative, world class life sciences companies and building experienced teams to accelerate transformative therapies for patients.”
Enquiries
For more information on Novo Holdings Seed Investments, please contact:
João Ribas, Principal
+45 2523 1546 (mobile)
Optimum Strategic Communications
Mary Clark, Hana Malik, Eleanor Cooper
+44 20 3922 0891
About Novo Holdings A/S
Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.
Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: www.novoholdings.dk.
